Can lab-grown heart muscle actually fix a failing heart?
In this early-phase human trial, patients with failing hearts were treated with transplanted patches of lab-grown heart muscle made from stem cells, and at three months the treated heart wall was thicker and pumping was modestly stronger. Every patient in the trial had at least one adverse event, so this is a first step, not a finished therapy.
This is a notable moment in heart medicine. For decades, doctors have wanted a way to actually rebuild damaged heart muscle instead of just managing symptoms. The BIOVAT-HF trial, an open-label phase 1-2 study of 20 patients, tested exactly that idea in people with heart failure and a left ventricular ejection fraction of 35% or less.
How the heart patches work
Heart failure happens when the heart muscle is too weak or damaged to pump enough blood. Once heart muscle dies, the body cannot grow it back. So scientists took a different approach. They used allogeneic induced pluripotent stem cells, meaning stem cells from a donor rather than the patient, and guided them to become heart muscle cells and stromal support cells. Those cells were grown into engineered heart muscle units, formulated into a graft called BioVAT, short for biologic ventricular assist tissue. Patients were eligible if they had at least one left ventricular segment that was hypokinetic or dyskinetic, meaning it moved poorly or moved the wrong way. Patients were treated with 5, 10, or 20 engineered heart muscle units, and all of them received immunosuppression to keep the immune system from rejecting the donor tissue.
What the trial found
Of the 16 patients treated at the safe maximal dose of 20 engineered heart muscle units, 12 completed the prespecified three-month interim follow-up. In that group, the targeted area of the heart wall thickened by a least-squares mean of 4.5 mm (90% CI, 3.7 to 5.4; p<0.001). Ejection fraction, the share of blood the heart squeezes out with each beat, rose by 3.9 percentage points (90% CI, 0.9 to 6.8; p=0.04). In advanced heart failure, that number starts dangerously low, so even a small absolute gain is worth measuring.
Patients also reported feeling somewhat better. The Kansas City Cardiomyopathy Questionnaire overall summary score, a standard measure of heart failure symptoms and daily function, increased by 6.7 points (90% CI, 1.0 to 12.5; p=0.06).
The safety picture is serious and needs stating plainly. All the patients had at least one adverse event. Three patients died during the study, one each from vasoplegia, COVID-19, and aortic dissection. One patient underwent heart transplantation. Immunosuppression was stopped in four patients: two after implantation of a left ventricular assist device, one for renal failure, and one for urothelial carcinoma.
Dr. Kumar’s Take
I have been waiting for a result like this for a long time. Heart failure is one of the hardest problems in medicine because the heart cannot heal itself the way skin or bone can. There are pumps, transplants, and medicines, but until now there has been no real way to put new muscle back into a damaged heart. The fact that lab-grown patches measurably thickened the heart wall and nudged pumping upward in living patients is genuinely important.
I want to be careful, though. This is an interim analysis of an early phase 1-2 study with 20 patients treated, only 12 of whom reached the three-month mark at the top dose. There was no control group, everyone knew who got the patch, and every single patient had an adverse event. Three patients died and one needed a transplant during the study. I do not know from this data how long the patches last, who responds best, or how any of it holds up in a larger, controlled trial. What I do take from it is that the concept works well enough in humans to justify going further, and that is a door that has been shut for a very long time.
Safety, limits, and caveats
The trial was open-label and small, meaning everyone knew who got the patch and there was no control group for comparison. The reported follow-up is a three-month interim analysis, so questions about long-term durability and rare side effects remain open, and the authors themselves say longer-term follow-up and further clinical investigation are warranted. Every patient in the trial had at least one adverse event. Patients also received immunosuppression, which carries its own infection and organ risks, and it had to be stopped in four patients. None of this erases the result, but it sets the stage for the bigger trials that need to follow.
Practical Takeaways
- If you or a loved one has advanced heart failure, ask your cardiologist about emerging regenerative therapies and clinical trials, since this field is moving quickly.
- Standard heart failure care still matters most right now, including medications, salt and fluid limits, exercise as tolerated, and treating high blood pressure and diabetes.
- Be cautious of clinics that already advertise stem cell heart treatments outside of formal trials, because BioVAT-style patches are still experimental and only studied in a small research setting.
- Track your symptoms over time, including breathlessness, swelling, and exercise tolerance, so your doctor can adjust treatment early if things change.
Related Studies and Research
- Chamomile tea improves sleep quality in elderly: clinical trial evidence
- Open water swimming as a treatment for major depressive disorder
- Red blood cells serve as a primary glucose sink to improve glucose tolerance at altitude
- Pantoprazole shows no increased kidney risk in major trial
FAQs
How is this different from a heart transplant or a mechanical heart pump?
A heart transplant replaces the entire failing heart with a donor heart, and a mechanical pump like an LVAD adds a machine to help the heart push blood. Both are major interventions with their own risks, like rejection, infection, and the lifelong need for medications or device care. The BioVAT approach is different because it adds new living heart muscle to the patient’s own heart, working alongside the tissue that is already there. The goal is remuscularization, rebuilding some pumping power rather than replacing or assisting the organ. Two patients in this trial went on to receive an LVAD anyway, and one received a transplant, so the approaches are not mutually exclusive at this stage.
Where do the stem cells in the patch come from, and is there any rejection risk?
The cells start as induced pluripotent stem cells, which are ordinary cells reprogrammed in the lab to act like stem cells. Scientists then guide them to become heart muscle cells and stromal supporting cells, and grow them into engineered heart muscle units. The cells in this trial were allogeneic, meaning they came from a donor rather than the patient, so the immune system can try to reject the graft. Every patient in the trial received immunosuppression for that reason, and it had to be discontinued in four of them. Longer studies will be needed to learn how to balance acceptance of the patch against the risks of those medications.
When could lab-grown heart patches become available to regular patients?
Realistically, not for several more years. This study is phase 1-2, which mostly tests safety and looks for early signs that something works, and what has been published so far is a three-month interim analysis of 20 treated patients. Larger controlled trials are needed to confirm the benefits, define who responds best, and watch for rare side effects over longer periods. After that, regulators have to review the data before any approval. The trial authors state that longer-term follow-up and further clinical investigation are warranted, which is the honest place this stands today.
Bottom Line
In an early trial, patients with failing hearts were treated with transplanted lab-grown heart muscle patches, and at three months the treated wall was 4.5 mm thicker, ejection fraction was up 3.9 percentage points, and symptom scores were up 6.7 points. The trial was small, open-label, and uncontrolled. Three patients died, one was transplanted, and every patient had at least one adverse event. The core idea, rebuilding damaged heart muscle instead of only managing the damage, has moved from theory into people. That is a real step, and the next step is a longer, larger, controlled trial.
